| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
3,5-Dibromopyridine does not have a defined biological target as it is a synthetic reagent rather than a pharmacologically active compound. Its function is chemical: it serves as a building block for the synthesis of more complex molecules. The two bromine substituents provide handles for sequential cross-coupling reactions (e.g., Suzuki, Buchwald, Sonogashira), enabling the construction of diverse pyridine derivatives. When incorporated into pharmaceutical compounds, the pyridine scaffold can interact with biological targets through hydrogen bonding, π-π stacking, and hydrophobic interactions. The compound itself is not evaluated for biological activity against specific targets.
|
|---|---|
| ln Vitro |
As a chemical reagent, 3,5-dibromopyridine exhibits no intrinsic pharmacological activity in vitro. Its utility is demonstrated in synthetic chemistry as a building block for the preparation of pharmaceuticals, agrochemicals, and materials. The compound's two bromine substituents enable sequential functionalization, making it a valuable intermediate in medicinal chemistry. In cell-based assays, the compound itself is not tested for biological activity. Instead, the products synthesized from this reagent are evaluated for their pharmacological properties. The compound is used exclusively as a chemical intermediate in organic synthesis.
|
| ln Vivo |
3,5-Dibromopyridine does not exhibit in vivo biological activity as it is not a therapeutic agent. The compound is used as a versatile chemical building block for pharmaceutical and agrochemical research. Any in vivo effects would be associated with the final products synthesized from this intermediate, not with the intermediate itself. The compound is not administered to animals in pharmacological studies and has no known physiological effects. Its role is strictly chemical—providing a versatile dibromopyridine scaffold.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to 3,5-dibromopyridine as it is not a biologically active compound. Standard characterization protocols for this reagent include nuclear magnetic resonance (¹H NMR, ¹³C NMR) and mass spectrometry to confirm structure and purity. Melting point determination (110-115°C) and HPLC analysis (98% purity) are used for quality control. For synthetic applications, typical reactions include sequential Suzuki-Miyaura couplings at the 3- and 5-positions, enabling the synthesis of unsymmetrically substituted pyridines. The resulting products are then evaluated for biological activity.
|
| Cell Assay |
Cell-based experiments are not performed with 3,5-dibromopyridine itself, as it is a chemical reagent rather than a test compound for biological activity. When the compound is used to synthesize drug candidates, those products may be tested in cell culture using standard protocols. Typically, final compounds are dissolved in DMSO and diluted in culture medium to achieve desired concentrations (typically 0.1-100 µM). Cells are incubated for 24-72 hours, and effects on cell viability, proliferation, or specific signaling pathways are measured using appropriate assays. The intermediate itself is not evaluated in cellular systems.
|
| Animal Protocol |
In vivo animal studies are not conducted with 3,5-dibromopyridine, as it is a research reagent for chemical synthesis. When the compound is used to synthesize drug candidates, those final products undergo standard preclinical evaluation. Typical protocols for drug candidates include pharmacokinetic studies in rodents (oral or intravenous administration, blood sampling for LC-MS/MS analysis), efficacy studies in disease models, and toxicology studies (acute and repeated-dose toxicity, histopathology). These studies evaluate the safety and efficacy of the final drug molecules, not the synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3,5-dibromopyridine are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 236.89, logP approximately 2.5-3.0), the compound would be expected to have moderate oral bioavailability if administered. The presence of two bromine atoms may affect metabolism, with potential for oxidative debromination. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies. For drug candidates synthesized from this intermediate, pharmacokinetic properties are determined as part of drug development.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3,5-dibromopyridine are limited as it is a research reagent. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored below 30°C. No acute toxicity data are available. The compound is not intended for drug, household, or other uses. It should be stored in a cool, dry place away from light and moisture.
|
| Additional Infomation |
3,5-Dibromopyridine is a dibromopyridine.
3,5-Dibromopyridine is a versatile chemical building block widely used in organic synthesis for the preparation of pharmaceuticals, agrochemicals, and materials. The two bromine substituents enable sequential cross-coupling reactions, allowing the synthesis of complex pyridine derivatives with diverse substitution patterns. It is a compound useful in organic synthesis. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—serving as a precursor for the synthesis of biologically active pyridine derivatives. |
| Molecular Formula |
C5H3BR2N
|
|---|---|
| Molecular Weight |
236.89
|
| Exact Mass |
234.863
|
| CAS # |
625-92-3
|
| Related CAS # |
3,5-Dibromopyridine-d3;1219799-05-9
|
| PubChem CID |
69369
|
| Appearance |
White to off-white solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
222.0±0.0 °C at 760 mmHg
|
| Melting Point |
110-115 °C(lit.)
|
| Flash Point |
84.3±21.8 °C
|
| Vapour Pressure |
0.2±0.4 mmHg at 25°C
|
| Index of Refraction |
1.607
|
| LogP |
2.73
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
68.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C([H])=NC([H])=C(C=1[H])Br
|
| InChi Key |
SOSPMXMEOFGPIM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3Br2N/c6-4-1-5(7)3-8-2-4/h1-3H
|
| Chemical Name |
3,5-dibromopyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2214 mL | 21.1068 mL | 42.2137 mL | |
| 5 mM | 0.8443 mL | 4.2214 mL | 8.4427 mL | |
| 10 mM | 0.4221 mL | 2.1107 mL | 4.2214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
